+

WO1997030997A1 - Derives du tropane, leur preparation et utilisation - Google Patents

Derives du tropane, leur preparation et utilisation Download PDF

Info

Publication number
WO1997030997A1
WO1997030997A1 PCT/EP1997/000850 EP9700850W WO9730997A1 WO 1997030997 A1 WO1997030997 A1 WO 1997030997A1 EP 9700850 W EP9700850 W EP 9700850W WO 9730997 A1 WO9730997 A1 WO 9730997A1
Authority
WO
WIPO (PCT)
Prior art keywords
tropane
dichlorophenyl
compound
chlorophenyl
alkyl
Prior art date
Application number
PCT/EP1997/000850
Other languages
English (en)
Inventor
Jørgen SCHEEL-KRÜGER
Peter Moldt
Frank Wätjen
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI9730163T priority Critical patent/SI0885220T1/xx
Priority to IL12514697A priority patent/IL125146A/en
Priority to AU17940/97A priority patent/AU720358B2/en
Priority to DK97903355T priority patent/DK0885220T3/da
Priority to SG9903902A priority patent/SG99853A1/en
Priority to CA002244773A priority patent/CA2244773C/fr
Priority to NZ330886A priority patent/NZ330886A/xx
Priority to BR9707636A priority patent/BR9707636A/pt
Priority to DE69705608T priority patent/DE69705608T2/de
Priority to JP52981097A priority patent/JP3238414B2/ja
Priority to AT97903355T priority patent/ATE203023T1/de
Priority to US09/101,524 priority patent/US6288079B1/en
Priority to PL97328503A priority patent/PL185132B1/pl
Priority to EE9800254A priority patent/EE04751B1/xx
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Priority to EP97903355A priority patent/EP0885220B1/fr
Priority to SK929-98A priority patent/SK281813B6/sk
Priority to UA98073814A priority patent/UA49872C2/uk
Priority to HU9901199A priority patent/HU228356B1/hu
Publication of WO1997030997A1 publication Critical patent/WO1997030997A1/fr
Priority to BG102637A priority patent/BG63945B1/bg
Priority to IS4825A priority patent/IS1824B/is
Priority to NO19983877A priority patent/NO318731B1/no
Priority to HK99104015A priority patent/HK1018957A1/xx
Priority to GR20010401690T priority patent/GR3036829T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof

Definitions

  • the present invention relates to novel tropane-derivatives which are valuable monoamine neurotransmitter, i.e dopamine, serotonin and noradrenaline, re-uptake inhibitors and the use of the novel tropane derivatives for the treatment of disorders or diseases responsive to the inhibition of monoamine neurotransmitter re-uptake, such as Parkinson's disease, depression, obsessive compulsive disorders, panic disorders, dementia, memory deficits, attention deficit hyperactivity disorder, obesity, anxiety, eating disorders and drug addiction or misuse, including cocaine abuse.
  • the brain consists of a plurality of neurons that communicate with each other via chemical messengers. Each neuron generates neurochemicals or neurotransmitters which act at sites being referred to as receptors on the cellular membrane of neurons.
  • One group of neurotransmitters referred to as the monoamine neurotransmitters, includes serotonin, dopamine and noradrenaline.
  • Monoamine neurotransmitters are released into the synaptic cleft between neurons in order to stimulate postsynaptic receptor activity.
  • the removal (or inactivation) of monoamine neurotransmitters occurs mainly by a reuptake mechanism into the presynaptic terminals. By inhibiting the re-uptake an enhancement of the physiological activity of monoamine neurotransmitters occur.
  • the serotonergic neural system of the brain have been shown to influence a variety of physiologic functions, and compounds having serotonin re-uptake inhibiting activity are predicted to have the ability to treat in mammals, including humans, a variety of disorders associated with this neural system, for example eating disorders, depression, obsessive compulsive disorders, panic disorders, alcoholism, pain, memory deficits and anxiety.
  • disorders related to depression such as pseudodementia or Ganser's syndrome, migraine pain, bulimia, obesity, pre-menstrual syndrome or late luteal phase syndrome, tobacco abuse, oanic disorder, post-traumatic syndrome, memory loss, dementia of ageing, acquired imn inodeficiencv syndrome dementia complex, memory dysfunction in ageing, social phobia, attention deficit hyperactivity disorder, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichotillomania.
  • the pathophysiology of major affective illness is poorly understood, and several neurotransmitters have been implicated in the pathophysiology of major depression.
  • Paradoxical currently used serotonin re-uptake inhibitors inhibit the serotonin transporter within minutes whereas their full anti-depressant effect is seen only after three to four weeks of treatment, indicating that re-uptake inhibition per se is not responsible for the antidepressant response, but rather that further adaptive changes underlie and/or contribute to their therapeutic effect.
  • the delayed onset of anti-depressant effect is considered to be a serious drawback to currently used monoamine re-uptake inhibitors.
  • a strong dopamine re-uptake inhibiting activity is considered with the risk of undesirable central stimulating effects.
  • an activating effect on the mesolimbic dopamine system is believed to underlay the commen mechanism of current antidepressant treatment by a mechanism which enhances the endogenous reward system.
  • Compounds with a strong serotonin re-uptake inhibiting activity combined with a well balanced moderate dopamine re-uptake inhibiting activity may therefore provide agents with a rapid onset of anti-depressant effect.
  • the compounds of the present invention are also valuable dopamine reuptake inhibitors and are as such considered useful for the treatment of Parkinsonism, depression, obesity, narcolepsy, drug addiction or misuse, including cocaine abuse, attention-deficit hyperactivity disorders, Gilles de la Tourettes disease and senile dementia.
  • Dopamine re ⁇ uptake inhibitors enhances indirectly via the dopamine neurones the release of acetylcholin and are therefore also useful for the treatment of memory deficits, e.g. in Alzheimers disease, presenile dementia, memory dysfuntion in ageing, and chronic fatigue syndrome.
  • Noradrenaline re-uptake inhibitors are considered useful for enhancing attention, alertness, arousal, vigilance and for treating depression.
  • disorders such as Parkinson's disease, depression and related diseases, obsessive compulsive disorders, panic disorders, dementia, memory deficits, attention deficit hyperactivity disorder, obesity, anxiety, eating disorders, drug addiction or misuse, including cocaine abuse.
  • Another object of the present invention is to provide novel pharmaceutical compositions containing the novel tropane-derivatives.
  • Still another object of the invention is to provide a method of treating diseases or disorders responsive to the inhibition of monoamine neurotransmitter re-uptake, such as Parkinsonism, depression and related diseases, obsessive compulsive disorders, panic disorders, dementia, memory deficits, attention deficit hyperactivity disorder, obesity, anxiety, eating disorders, drug addiction or misuse, including cocaine abuse.
  • diseases or disorders responsive to the inhibition of monoamine neurotransmitter re-uptake such as Parkinsonism, depression and related diseases, obsessive compulsive disorders, panic disorders, dementia, memory deficits, attention deficit hyperactivity disorder, obesity, anxiety, eating disorders, drug addiction or misuse, including cocaine abuse.
  • the invention then, inter alia, comprises the following, alone or in combination:
  • R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl or 2-hydroxyethyl;
  • R 3 is CH 2 -X-R', wherein X is O, S, or NR", wherein R" is hydrogen, or alkyl, and R' is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, or -CO-alkyl;
  • R 4 is phenyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF 3 , CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl;
  • benzyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF 3 , CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl; heteroaryl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF 3 , CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl; or naphthyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF 3 , CN, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, heteroaryl and aryl and
  • composition comprising an therapeuticallly effective amount of a compound as any above, or a pharmaceutically acceptable addition salt thereof, together with at least one pharmaceutically acceptable carrier or diluent;
  • a compound as any above for the manufacture of a medicament for the treatment of a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to the inhibition of monoamine neurotransmitter reuptake in the central nervous system;
  • R and R 4 is as defined in claim 1 , with an alcoholate R'-Z-Na, wherein R' is as defined in claim 1 and Z is O, or S to form a compound of the invention wherein X is O, or S;
  • R and R 4 is as defined in claim 1 , with an amine NHR"-R' to form a compound of the invention wherein X is NR"; or
  • R and R 4 is as defined in claim 1 , with sodium hydride and a compound having the formula R'-SO 2 to form a compound of the invention wherein X is O;
  • a method of treating a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to the inhibition of monoamine neurotransmitter reuptake comprising the step of administering to such a living animal body, including a human, in need thereof a therapeutically effective amount of a compound as any above;
  • addition salts include inorganic and organic acid addition salts such as the hydrochloride, hydrobromide, phosphate, nitrate, perchlorate, sulphate, citrate, lactate, tartrate, maleate, fumarate, mandelate, benzoate, ascorbate, cinnamate, benzenesulfonate, methanesulfonate, stearate, succinate, glutamate, glycollate, toluene-p-sulphonate, formate, malonate, naphthalene-2- suiphonate, saiicylate and the acetate.
  • Such salts are formed by procedures well known in the art.
  • acids such as oxalic acid, while not in themselves pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining compounds of the invention and their pharmaceutically acceptable acid addition salts.
  • Halogen is fluorine, chlorine, bromine or iodine.
  • Alkyl means a straight chain or branched chain of one to six carbon atoms, including but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl; methyl, ethyl, propyl and isopropyl are preferred groups.
  • Cycloalkyl means cyclic alkyl of three to seven carbon atoms, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;
  • Alkenyl means a group of from two to six carbon atoms, including at least one double bond, for example, but not limited to ethenyl, 1,2- or 2,3-propenyl, 1 ,2-, 2,3-, or 3,4- butenyl.
  • Alkynyl means a group of from two to six carbon atoms, including at least one triple bond, for example, but not limited to ethynyl, 2,3-propynyl, 2,3- or 3,4-butynyl.
  • Cycloalkylalkyl means cycloalkyl as above and alkyl as above, meaning for example, cyclopropylmethyl.
  • Alkoxy is O-alkyl, wherein alkyl is as defined above.
  • Cycloalkoxy is O-cycloalkyl, wherein cycloalkyl is as defined above.
  • Amino is NH 2 or NH-alkyl or N-(alkyl) 2 , wherein alkyl is as defined above.
  • Heteroaryl is a 5- or 6-membered heterocyclic monocyclic group.
  • Such an heteroaryl group includes, for example, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol- 4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1 ,2,4-oxadiazol-3-yl, 1 ,2,4-oxadiazol-5-yl, 1,2,4-thiadiazol-3-yl, 1,2,4- thiadiazol-5-yl, 1,2,5-oxadiazol-3-yl, 1 ,2,5-oxadiazol-4-yl, 1 ,2,5-thiadiazol-3-yl, 1 ,2,5
  • Aryl is an aromatic hydrocarbon, such as phenyl and naphthyl.
  • the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like.
  • the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
  • Racemic forms can be resolved into the optical antipodes by known methods, for example, by separation of diastereomeric salts thereof with an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallization of d- or I- (tartrates, mandelates, or camphorsulphonate) salts for example.
  • the compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the compounds of the present invention with an optically active chloroformate or the like.
  • an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid
  • Optical active compounds can also be prepared from optical active starting materials.
  • a compound of the invention can be converted to another compound of the invention using conventional methods.
  • the compounds of the present invention have been tested for their ability to bind to the dopamine transporter in the following tests for in vitro inhibition of 3 H-WIN 35428.
  • Dopamine transporters/uptake sites on nerve terminals presumably function to terminate neuronal signaling by removing dopamine from the synaptic cleft.
  • the activity or presence of the dopamine transporter integral protein can be measured in vitro with synaptosomal uptake of 3 H-dopamine or membrane binding assays with 3 H-ligands known to bind to the transporter.
  • Tissue preparation Preparations are performed at 0-4°C unless otherwise indicated.
  • Corpus striatum from male Wistar rats (150-200 g) is homogenized for 5-10 sec in 10 ml NaH 2 PO 4 (50 mM, pH 7.4) using an Ultra-Turrax homogenizer. The suspension is centrifuged at 27,000 x g for 15 min. The supernatant is discarded and the pellet is resuspended in 50 mM NaH 2 PO 4 , pH 7.4 (1000 ml per g of original tissue) and used for binding assays.
  • Assay Aliquots of 0.5 ml tissue are added to 25 ml of test solution and 25 ml of 3 H-WIN 35428 (1 nM, final concentration), mixed and incubated for 60 min at 2°C. Non-specific binding is determined using cocaine (30 mM, final concentration). After incubation the samples are added 5 ml of ice-cold buffer and poured directly onto Whatman GF/C glass fibre filters under suction and immediately washed with 5 ml ice-cold buffer. The amount of radioactivity on the filters is determined by conventional liquid scintillation counting. Specific binding is total binding minus non-specific binding.
  • IC 50 the concentration ( ⁇ M) of the test substance which inhibits the specific binding of 3 H-WIN 35428 by 50%.
  • test results presented above show that the compounds of the invention binds with high affinity to the dopamine transporter complex.
  • Specific neurotransmitter transporters/uptake sites on nerve terminals presumably function to terminate neuronal signaling by removing the neurotransmitters dopamine, noradrenaline and serotonin, respectively, from the synaptic cleft.
  • the activity of the transporter integral proteins can be measured in vitro by synaptosomal uptake of 3 H- dopamine, 3 H-noradrenaline and 3 H-serotonin, respectively.
  • Tissue preparations Preparations are performed at 0-4°C unless otherwise indicated.
  • Corpi striati from male Wistar rats (150-200 g) are homogenized for 5-10 sec in 100 volumes of ice-cold 0.32M sucrose containing 1 mM pargyline using an Ultra-Turrax homogenlzer. Monoamine oxidase activity will be inhibited in the presence of pargyline.
  • the homogenate is centrifuged at 1000 x g for 10 min. The resulting supernatant is then centrifuged at 27,000 x g for 50 min and the supernatant is discarded.
  • the pellet (P 2 ) is resuspended in oxygenated (equilibrated with an atmosphere of 96% O 2 : 4% C0 2 for at least 30 min) Krebs-Ringer incubation buffer (8000 ml per g of original tissue) at pH 7.2 containing 122 mM NaCl, 0.16 mM EDTA, 4.8 mM KCl, 12.7 mM Na 2 HPO 4 , 3.0 mM NaH 2 PO 4 , 1.2 mM MgSO 4 , 1 mM CaCI 2 , 10 mM glucose and 1 mM ascorbic acid.
  • IC 50 the concentration ( ⁇ M) of the test substance which inhibits the specific binding of 3 H-DA by 50%.
  • Tissue preparation Preparations are performed at 0-4°C unless otherwise indicated. Hippocampi from male Wistar rats (150-200 g) are homogenized for 5-10 sec in 100 volumes of ice-cold 0.32M sucrose containing 1 mM pargyline using an Ultra-Turrax homogenizer. Monoamine oxidase activity will be inhibited in the presence of pargyline. The homogenate is centrifuged at 1000 x g for 10 min. The resulting supernatant is then centrifuged at 27,000 x g for 50 min and the supernatant is discarded.
  • the pellet (P 2 ) is resuspended in oxygenated (equilibrated with an atmosphere of 96% O 2 : 4% CO 2 for at least 30 min) Krebs-Ringer incubation buffer (2000 ml per g of original tissue) at pH 7.2 containing 122 mM NaCl, 0.16 mM EDTA, 4.8 mM KCl, 12.7 mM Na 2 HPO 4 , 3.0 mM NaH 2 PO 4 , 1.2 mM MgSO 4 , 0.97 mM CaCI 2 , 10 mM glucose and 1 mM ascorbic acid.
  • IC ⁇ the concentration ( ⁇ M) of the test substance which inhibits the specific binding of 3 H-NA by 50%).
  • Tissue preparation Preparations are performed at 0-4°C unless otherwise indicated. Cerebral cortices from male Wistar rats (150-200 g) are homogenized for 5-10 sec in 100 volumes of ice-cold 0.32M sucrose containing 1 M pargyline using an Ultra-Turrax homogenizer. Monoamine oxidase activity will be inhibited in the presence of pargyline. The homogenate is centrifuged at 1000 x g for 10 min. The resulting supernatant is then centrifuged at 27,000 x g for 50 min and the supernatant is discarded.
  • the pellet (P 2 ) is resuspended in oxygenated (equilibrated with an atmosphere of 96% O 2 : 4% CO 2 for at least 30 min) Krebs-Ringer incubation buffer (1000 ml per g of original tissue) at pH 7.2 containing 122 mM NaCl, 0.16 mM EDTA, 4.8 mM KCl, 12.7 M Na 2 HPO 4 , 3.0 mM NaH 2 PO 4 , 1.2 mM MgSO 4 , 1 mM CaCI 2 , 10 mM glucose and 1 mM ascorbic acid.
  • Krebs-Ringer incubation buffer 1000 ml per g of original tissue at pH 7.2 containing 122 mM NaCl, 0.16 mM EDTA, 4.8 mM KCl, 12.7 M Na 2 HPO 4 , 3.0 mM NaH 2 PO 4 , 1.2 mM MgSO 4 , 1 mM CaCI 2 , 10 mM glucose and 1
  • the test value is given as IC ⁇ > (the concentration ( ⁇ M) of the test substance which inhibits the specific binding of 3 H-5-HT by 50%).
  • a compound of the invention may be administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation.
  • the invention thus further provides pharmaceutical formulations comprising a compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • compositions include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub ⁇ cutaneous and intravenous) administration or in a form suitable for administration by inhatation or insufflation.
  • compositions and unit dosages thereof may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.
  • Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • Formulations containing ten (10) milligrams of active ingredient or, more broadly, 0.1 to one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
  • the compounds of the present invention can be administrated in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.
  • pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from five or ten to about seventy percent of the active compound.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
  • a low melting wax such as admixture of fatty acid glycerides or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions.
  • parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
  • the compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formuiatory agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • These preparations may contain, in addition to the active component, colorants, flavours, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
  • Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
  • the formulations may be provided in single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomising spray pump.
  • Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifiuoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifiuoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • CFC chlorofluorocarbon
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • the dose of drug may be controlled by provision of a metered valve.
  • the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • a powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • PVP polyvinylpyrrolidone
  • the powder carrier will form a gel in the nasal cavity.
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
  • the compound In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
  • formulations adapted to give sustained release of the active ingredient may be employed.
  • the pharmaceutical preparations are preferably in unit dosage forms, in such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.
  • the compounds of the present invention are useful in the treatment of disorders or diseases responsive to the monoamine neurotransmitter re-uptake inhibiting activity of the compounds.
  • This activity of the compounds of the invention make them extremely useful in the treatment of, parkinsonism, depression, obesity, narcolepsy, drug abuse, e.g cocaine misuse, attention-deficit hyperactivity disorders, senile dementia and coqnitive dysfunction as well as other disorders sensitive to the monoamine neurotransmitter reuptake-inhibiting activity of the compounds.
  • the compounds of this invention may accordingly be administered to a living animal body, including a human, in need of treatment, alleviation, or elimination of an indication associated with or responsive to monoamine neurotransmitter uptake-inhibiting activity.
  • Suitable dosage range are 0.1-500 milligrams daily, and especially 10-70 milligrams daily, administered once or twice a day, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
  • I.p. means intraperetoneally, which is a well known route of administration.
  • P.O. means peroral, which is a well known route of administration.
  • Grignard reagent was made in a three necked reaction flask equipped with mechanical stirring, an intensive condenser and a pressure equilibrated funnel, using 4-bromo- fluorobenzene (27.5 ml , 250 mmol) and magnesium turnings (6.3 g, 260 mmol) in 250 ml absolute diethyl ether.
  • the solution of grignard reagent was cooled to -20° C and a solution of (-)-anhydroecgonine methyl ester (21.7 g, 120 mmol) in 100 ml absolute diethyl ether was added over 1/2 hour.
  • the reaction was stirred one hour at -20° C and the reaction was quenched in one of the following two ways:
  • the fumarate salt of the above compound was prepared as follows:
  • the fumarate salt was formed by dissolving the product in ethanol and adding fumaric acid in ethanol ( 0.25 M). The salt was filtered off, washed with ethanol and dried. M.p. 220-222 ° C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne les composés présentant la formule (a), (b), (c) ou (d) ou un mélange de ces derniers, ou un sel pharmaceutiquement acceptable de ces derniers; où R est de l'hydrogène, alkyle, alcényle, alkynyle, cycloalkyle, cycloalkylalkyle ou 2-hydroxyéthyle; R3 est -CH¿2?-X-R', où X est O, S ou NR', où R' est de l'hydrogène, ou de l'alkyle et R' est de l'alkyle, alcényle, alkynyle, cycloalkyle, cycloalkylalkyle, ou -CO-alkyle; R?4¿ est du phényle qui peut être substitué une ou plusieurs fois avec des substituants sélectionnés dans le groupe se composant d'halogène, CF¿3?, CN, alcoxy, cycloalcoxy, alkyle, cycloalkyle, alcényle, alkynyle, amino, nitro, hétéroaryle et aryle; du 3,4-méthylènedioxyphényle; du benzyle qui peut être substitué une ou plusieurs fois avec des substituants sélectionnés dans le groupe se composant d'halogène, CF3, CN, alcoxy, cycloalcoxy, alkyle, cycloalkyle, alcényle, alkynyle, amino, nitro, hétéroaryle et aryle; de l'hétéroaryle qui peut être substitué une ou plusieurs fois avec des substituants sélectionnés dans le groupe se composant d'halogène, CF3, CN, alcoxy, cycloalcoxy, alkyle, cycloalkyle, alcényle, alkynyle, amino, nitro, hétéroaryle et aryle; du naphtyle qui peut être substitué une ou plusieurs fois avec des substituants sélectionnés dans le groupe se composant d'halogène, CF3, CN, alcoxy, cycloalcoxy, alkyle, cycloalkyle, alcényle, alkynyle, amino, nitro, hétéroaryle et aryle. Ces composés présentent des propriétés pharmaceutiques intéressantes en tant qu'inhibiteurs de la recapture de neuromédiateurs de monoamine, c'est-à-dire, de la dopamine, de la sérotonine, de la noradrénaline.
PCT/EP1997/000850 1996-02-22 1997-02-21 Derives du tropane, leur preparation et utilisation WO1997030997A1 (fr)

Priority Applications (23)

Application Number Priority Date Filing Date Title
PL97328503A PL185132B1 (pl) 1996-02-22 1997-02-21 Pochodne tropanowe, ich wytwarzanie i zastosowanie, oraz zawierająca je kompozycja farmaceutyczna
AU17940/97A AU720358B2 (en) 1996-02-22 1997-02-21 Tropane-derivatives, their preparation and use
DK97903355T DK0885220T3 (da) 1996-02-22 1997-02-21 Tropanderivater, deres fresmtilling og anvendelse
SG9903902A SG99853A1 (en) 1996-02-22 1997-02-21 Tropane-derivatives, their preparation and use
CA002244773A CA2244773C (fr) 1996-02-22 1997-02-21 Derives du tropane, leur preparation et utilisation
NZ330886A NZ330886A (en) 1996-02-22 1997-02-21 Tropane derivatives, their preparation and use
BR9707636A BR9707636A (pt) 1996-02-22 1997-02-21 Composto composição farmacêutica uso de um composto e processos para preparar composto e para tratar um distúrbio ou doença de um organismo animal vivo
DE69705608T DE69705608T2 (de) 1996-02-22 1997-02-21 Tropanderivate, deren herstellung und verwendung
IL12514697A IL125146A (en) 1996-02-22 1997-02-21 History - 3phenyl - 2 (methyl converted) Tropan, their preparation and pharmaceutical preparations containing them
AT97903355T ATE203023T1 (de) 1996-02-22 1997-02-21 Tropanderivate, deren herstellung und verwendung
US09/101,524 US6288079B1 (en) 1996-02-22 1997-02-21 Tropane-derivatives, their preparation and use
SI9730163T SI0885220T1 (en) 1996-02-22 1997-02-21 Tropane-derivatives, their preparation and use
JP52981097A JP3238414B2 (ja) 1996-02-22 1997-02-21 トロパン―誘導体、その製造方法及びその使用方法
EE9800254A EE04751B1 (et) 1996-02-22 1997-02-21 Tropaani derivaadid, nende valmistamine ja kasutamine
EP97903355A EP0885220B1 (fr) 1996-02-22 1997-02-21 Derives du tropane, leur preparation et utilisation
SK929-98A SK281813B6 (sk) 1996-02-22 1997-02-21 Tropánové deriváty, spôsob ich prípravy, použitie a farmaceutická kompozícia s ich obsahom
UA98073814A UA49872C2 (uk) 1996-02-22 1997-02-21 Похідні тропану, спосіб їх одержання, фармацевтична композиція та спосіб лікування
HU9901199A HU228356B1 (en) 1996-02-22 1997-02-21 Tropane-derivatives, inhibiting neurotransmitter re-uptake, their preparation, pharmaceutical compositions containing them and use of the compounds
BG102637A BG63945B1 (bg) 1996-02-22 1998-07-15 Тропанови производни, тяхното получаване и приложение
IS4825A IS1824B (is) 1996-02-22 1998-08-17 Trópan-afleiður, gerð þeirra og notkun
NO19983877A NO318731B1 (no) 1996-02-22 1998-08-21 Tropanderivater, farmasoytiske preparater som omfatter forbindelsene, anvendelse av forbindelsene til fremstilling av medikamenter og fremgangsmate for fremstilling av forbindelsene.
HK99104015A HK1018957A1 (en) 1996-02-22 1999-09-17 Tropane-derivatives, their preparation and use
GR20010401690T GR3036829T3 (en) 1996-02-22 2001-10-08 Tropane-derivatives, their preparation and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK0194/96 1996-02-22
DK19496 1996-02-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/101,524 A-371-Of-International US6288079B1 (en) 1996-02-22 1997-02-21 Tropane-derivatives, their preparation and use
US09/814,413 Continuation US6395748B2 (en) 1996-02-22 2001-03-21 Tropane-derivatives, their preparation and use

Publications (1)

Publication Number Publication Date
WO1997030997A1 true WO1997030997A1 (fr) 1997-08-28

Family

ID=8090830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/000850 WO1997030997A1 (fr) 1996-02-22 1997-02-21 Derives du tropane, leur preparation et utilisation

Country Status (32)

Country Link
US (3) US6288079B1 (fr)
EP (2) EP0885220B1 (fr)
JP (1) JP3238414B2 (fr)
KR (1) KR100446571B1 (fr)
CN (1) CN1077574C (fr)
AT (1) ATE203023T1 (fr)
AU (1) AU720358B2 (fr)
BG (1) BG63945B1 (fr)
BR (1) BR9707636A (fr)
CA (1) CA2244773C (fr)
CZ (1) CZ287007B6 (fr)
DE (1) DE69705608T2 (fr)
DK (1) DK0885220T3 (fr)
EE (1) EE04751B1 (fr)
ES (1) ES2159839T3 (fr)
GR (1) GR3036829T3 (fr)
HK (1) HK1018957A1 (fr)
HU (1) HU228356B1 (fr)
IL (1) IL125146A (fr)
IS (1) IS1824B (fr)
NO (1) NO318731B1 (fr)
NZ (1) NZ330886A (fr)
PL (1) PL185132B1 (fr)
PT (1) PT885220E (fr)
RU (1) RU2167876C2 (fr)
SG (1) SG99853A1 (fr)
SI (1) SI0885220T1 (fr)
SK (1) SK281813B6 (fr)
TR (1) TR199801641T2 (fr)
UA (1) UA49872C2 (fr)
WO (1) WO1997030997A1 (fr)
ZA (1) ZA971525B (fr)

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1118674A1 (fr) * 1998-09-30 2001-07-25 Nihon Medi-Physics Co., Ltd. Procede de production d'un derive d'acide tropinone-monocarboxylique optiquement actif
WO2002102801A1 (fr) * 2001-05-23 2002-12-27 Neurosearch A/S Derives du tropane et utilisation de ces derniers comme inhibiteurs de recaptage du neurotransmetteur monoamine
WO2003045388A1 (fr) * 2001-11-30 2003-06-05 Neurosearch A/S Derives de tropane possedant une activite inhibitrice de recaptage de dopamine destines au traitement de maladies ischemiques
WO2003101453A1 (fr) * 2002-05-30 2003-12-11 Neurosearch A/S Triple inhibiteurs de recaptage de momoamine pour le traitement de douleur chronique
WO2004039778A1 (fr) 2002-11-01 2004-05-13 Neurosearch A/S Nouveaux derives de piperidine et leur utilisation en tant qu'inhibiteurs de recaptage de neurotransmetteurs de la monoamine
WO2004072075A1 (fr) 2003-02-12 2004-08-26 Neurosearch A/S Nouveaux derives de 8-aza-bicyclo[3.2.1]octane et leur utilisation en tant qu'inhibiteurs du recaptage des neurotransmetteurs monoamines
WO2004072071A1 (fr) 2003-02-12 2004-08-26 Neurosearch A/S 8 nouveaux derives de 8-aza-bicyclo[3.2.1]octane et leur utilisation en tant qu'inhibiteurs du recaptage des neurotransmetteurs monoamines
US6794361B1 (en) 1998-10-02 2004-09-21 The University Of Queensland Peptides
WO2005011694A1 (fr) * 2003-07-31 2005-02-10 Neurosearch A/S Sels de 2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1] octane tartrate
WO2005039580A1 (fr) 2003-10-16 2005-05-06 Boehringer Ingelheim International Gmbh Composition pharmaceutique comprenant un inhibiteur de la recapture des neurotransmetteurs de monoamine et un inhibiteur de l'acetylcholinesterase
WO2005049024A2 (fr) * 2003-11-18 2005-06-02 Boehringer Ingelheim International Gmbh Forme de preparation pharmaceutique solide
WO2005070429A1 (fr) * 2004-01-22 2005-08-04 Neurosearch A/S Preparation pharmaceutique contenant un inhibiteur de recapture du neurotransmetteur monoamine et un antagoniste des recepteurs du n-methyl-d-aspartate (nmda)
WO2005070427A1 (fr) 2004-01-22 2005-08-04 Neurosearch A/S Composes utilises pour perdre du poids de maniere durable
WO2005070428A1 (fr) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Composition pharmaceutique contenant un inhibiteur de la recapture de neurotransmetteurs monoamine et un agoniste de la dopamine
WO2005073228A1 (fr) 2004-01-31 2005-08-11 Neurosearch A/S Procede pour produire un derive de 2-(ethoxymethyl)-tropane
WO2005123728A1 (fr) * 2004-06-18 2005-12-29 Neurosearch A/S Nouveaux derives de 9-aza-bicyclo[3.3.1]nonane et leur utilisation comme inhibiteurs du recaptage des neurotransmetteurs monoamines
WO2005123679A2 (fr) 2004-06-18 2005-12-29 Neurosearch A/S Nouveaux derives de piperidine substitues par alkyle et leur utilisation comme inhibiteurs de recaptage de neurotransmetteur de monoamine
WO2006084870A2 (fr) 2005-02-10 2006-08-17 Neurosearch A/S Nouveaux derives d'homopiperazine substitues alkyle et leur utilisation en tant qu'inhibiteurs du recaptage des neurotransmetteurs de monoamine
WO2007000465A1 (fr) * 2005-06-28 2007-01-04 Neurosearch A/S Nouveaux derives de 3-aza-spiro[5.5]undecane et leur utilisation comme inhibiteurs de la recapture des neurotransmetteurs monoaminergiques
WO2007011820A2 (fr) 2005-07-15 2007-01-25 Amr Technology, Inc. Tetrahydrobenzazepines substituees par aryle et heteroaryle, et leur utilisation pour bloquer la reabsorption de la noradrenaline, de la dopamine, et de la serotonine
EP1779851A1 (fr) 2005-10-31 2007-05-02 Boehringer Ingelheim Pharma GmbH & Co.KG Traitement du diabète
WO2007054531A1 (fr) * 2005-11-11 2007-05-18 Neurosearch A/S Dérivés de 8-aza-bicyclo[3.2.1]octane et leur utilisation en tant qu'inhibiteurs de recapture de neurotransmetteur monoamine
WO2007093604A1 (fr) 2006-02-17 2007-08-23 Neurosearch A/S Nouveaux dérivés de chromen-2-one et leurs utilisation en tant qu'inhibiteurs de recaptage d'un neuro-transmetteur monoamine
US7309790B2 (en) 2003-10-03 2007-12-18 Pfizer Inc Chemical compounds
CN100368409C (zh) * 2003-06-24 2008-02-13 神经研究公司 8-氮杂双环[3.2.1]辛烷衍生物及其用于制备单胺神经递质再摄取抑制剂的用途
WO2008104584A1 (fr) * 2007-03-01 2008-09-04 Glaxo Group Limited Sel chlorhydrate d'un dérivé d'azabicyclo[3.2.1]octane
JP2009500440A (ja) * 2005-07-12 2009-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 性欲障害治療用医薬組成物
WO2009034043A1 (fr) * 2007-09-10 2009-03-19 Neurosearch A/S Nouveaux dérivés de phénoxazin-3-one et leur utilisation comme inhibiteurs de la recapture des neurotransmetteurs monoamines
WO2009034042A1 (fr) * 2007-09-10 2009-03-19 Neurosearch A/S Nouveaux dérivés de benzooxazol-2-one et de benzooxathiol-2-one ainsi que leur utilisation comme inhibiteurs de la recapture des neurotransmetteurs monoamines
US7507717B2 (en) 2002-12-02 2009-03-24 Xenome Ltd. Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)
US7524958B2 (en) 2004-06-18 2009-04-28 Neurosearch A/S Certain 9-aza-bicyclo[3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2009065846A1 (fr) * 2007-11-20 2009-05-28 Neurosearch A/S Procédé de traitement de l'accoutumance
WO2009065845A1 (fr) * 2007-11-20 2009-05-28 Neurosearch A/S Procédé de traitement des troubles d'hyperphagie
US7700596B2 (en) 2006-02-10 2010-04-20 Neurosearch A/S 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2010130620A1 (fr) 2009-05-15 2010-11-18 Neurosearch A/S Dérivés de chromén-2-one et leur utilisation comme inhibiteurs de re-captage de neurotransmetteurs monoamines
WO2010132487A1 (fr) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company Formes cristallines de (s)-7-([1,2,4]triazolo[1,5-a] pyridin -6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et leurs utilisations
WO2010132442A1 (fr) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2, 4,]triazolo[1,5,-a]pyridine-6-yl)-4-(3,4-dichlorophényl)-1,2,3,4- tétrahydroisoquinoline et son utilisation
EP2255848A2 (fr) 2006-09-04 2010-12-01 NeuroSearch AS Combinaisons pharmaceutiques contenant un modulateur du récepteur de la nicotine et un facilitateur cognitif
US7851444B2 (en) 2002-12-02 2010-12-14 Xenome Ltd. χ-conotoxin peptides (-1)
EP2272847A1 (fr) 2005-04-08 2011-01-12 NeuroSearch A/S Enantiomères et leur utilisation comme inhibiteurs du recaptage des neurotransmetteurs monoamine
EP2284170A1 (fr) 2004-09-30 2011-02-16 NeuroSearch AS Noveaux derivés de chromene-2-one et leur utilisation comme inhibiteurs de recapture du neurotransmetteur monoamine
WO2011032903A1 (fr) 2009-09-21 2011-03-24 Neurosearch A/S Dérivés de pipérazinyl-alkyl-benzoimidazol-2-one et leur utilisation comme inhibiteurs de recaptage de neurotransmetteurs monoamines
WO2011092061A1 (fr) 2010-01-29 2011-08-04 Neurosearch A/S Dérivés du chromen-2-one et leur utilisation comme inhibiteurs de la recapture des neurotransmetteurs monoamines
WO2011117289A1 (fr) 2010-03-25 2011-09-29 Neurosearch A/S Dérivés de chromén-2-one et leur utilisation à titre d'inhibiteurs de recaptage des neurotransmetteurs monoaminés
WO2012000881A1 (fr) 2010-07-02 2012-01-05 Neurosearch A/S Dérivés de chromén-2-one et leur utilisation comme inhibiteurs de la résorption de neurotransmetteurs monoamine
WO2012024397A2 (fr) 2010-08-17 2012-02-23 Albany Molecular Research, Inc. Dérivés 2,5-méthano- et 2,5-éthano-tétrahydrobenzazépine et utilisation de ceux-ci pour bloquer le recaptage de la norépinéphrine, de la dopamine, et de la sérotonine
WO2012046882A1 (fr) 2010-10-07 2012-04-12 Takeda Pharmaceutical Company Limited Dérivés de 1,4-oxazépane
US8410271B2 (en) 2004-09-30 2013-04-02 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2013120935A1 (fr) 2012-02-16 2013-08-22 Neurosearch A/S Compositions pharmaceutiques pour traitement combiné
WO2016138908A1 (fr) 2015-03-03 2016-09-09 Saniona A/S Formulation à base de combinaison de tésofensine et de bêta-bloquant
WO2017121432A1 (fr) 2016-01-15 2017-07-20 Saniona A/S Tésofensine et métoprolol pour le traitement de l'hypertension
WO2017144978A1 (fr) * 2016-02-25 2017-08-31 Замертон Холдинге Лимитед Sels de (1r,2r,3s)-3-(3,4-dichlorophényl)-2-(étoxyméthyl)-8-méthyl-8-azabicyclo[3.2.1]octane et d'acétalaminoacides optiquement actifs et leur utilisation pour le traitement de troubles liés à l'obésité
WO2018046599A1 (fr) 2016-09-07 2018-03-15 Saniona A/S Compositions de tesofensine
WO2020144146A1 (fr) 2019-01-07 2020-07-16 Saniona A/S Tesofensine pour la réduction du poids corporel chez des patients prader-willi
WO2021214233A1 (fr) 2020-04-22 2021-10-28 Saniona A/S Traitement de l'obésité hypothalamique
WO2024008808A1 (fr) 2022-07-08 2024-01-11 Initiator Pharma A/S Composé pour le traitement d'un dysfonctionnement sexuel féminin
WO2024089247A1 (fr) 2022-10-28 2024-05-02 Initiator Pharma A/S Composé pour le traitement de la douleur
WO2024146892A1 (fr) 2023-01-03 2024-07-11 Initiator Pharma A/S Composé pour le traitement d'un dysfonctionnement érectile
WO2025051846A1 (fr) 2023-09-05 2025-03-13 Initiator Pharma A/S Composé pour le traitement d'un dysfonctionnement sexuel féminin

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2506646A1 (fr) * 2001-10-11 2003-04-11 Organix, Inc. Inhibiteurs du transport de la serotonine
WO2003037313A2 (fr) * 2001-10-31 2003-05-08 Recovery Pharmaceuticals, Inc. Methodes de traitement de la toxicomanie
CN100551924C (zh) * 2003-02-12 2009-10-21 神经研究公司 8-氮杂-双环[3.2.1]辛烷衍生物和它们作为单胺神经递质再摄取抑制剂的用途
CN100372850C (zh) * 2003-02-12 2008-03-05 神经研究公司 新的8-氮杂-双环[3.2.1]辛烷衍生物和它们作为单胺神经递质再摄取抑制剂的用途
WO2005117874A1 (fr) * 2004-06-04 2005-12-15 Neurosearch A/S INHIBITEUR DU RECAPTAGE DU NEUROTRANSMETTEUR MONOAMINE DESTINE A INHIBER LA GENERATION DE BETA-AMYLOIDE (Ass40 ET Ass42)
US7704991B2 (en) * 2005-04-04 2010-04-27 Neurosearch A/S Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
JP2008546827A (ja) * 2005-06-28 2008-12-25 ノイロサーチ アクティーゼルスカブ 新規な３−アザ−スピロ［５．５］ウンデカ−８−エン誘導体及びモノアミン神経伝達物質再取り込み阻害剤としてのこれらの使用
US8093388B2 (en) * 2005-06-28 2012-01-10 Neurosearch A/S 3-aza spiro[5,5]undec-8-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
JP2008546826A (ja) * 2005-06-28 2008-12-25 ノイロサーチ アクティーゼルスカブ 新規な３，９−ジアザ−スピロ［５．５］ウンデカン誘導体及びモノアミン神経伝達物質再取り込み阻害剤としてのこれらの使用
EP1919476A2 (fr) 2005-08-24 2008-05-14 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Derives de benzotropine et leurs utilisations comme inhibiteurs de recapture de la dopamine
WO2007028769A1 (fr) * 2005-09-05 2007-03-15 Neurosearch A/S Inhibiteur de recaptage de neurotransmetteur monoamine pour la neuroprotection
WO2007028770A1 (fr) * 2005-09-05 2007-03-15 Neurosearch A/S Inhibiteurs du recaptage du neurotransmetteur monoamine pour une neuroprotection chez des patients souffrant d'une maladie mentale avancée
US7691893B2 (en) * 2006-09-11 2010-04-06 Glaxo Group Limited Chemical compounds
TW200904815A (en) 2007-05-09 2009-02-01 Neurosearch As Novel compounds
US8153653B2 (en) * 2010-06-22 2012-04-10 Hoffmann-La Roche Inc. Amido-tropane derivatives
EA026727B1 (ru) * 2015-09-10 2017-05-31 Замертон Холдингс Лимитед Соль (1r,2r,3s)-3-(3,4-дихлорфенил)-2-(этоксиметил)-8-метил-8-азабицикло[3.2.1]октана и фталевой кислоты, способ её получения, продукт способа, фармацевтические композиции для лечения и/или профилактики нарушений, связанных с ожирением, их применение и способы лечения и/или профилактики нарушений, связанных с ожирением
DE102017210141A1 (de) 2017-06-16 2018-12-20 Henkel Ag & Co. Kgaa Portion zur Bereitstellung tensidhaltiger Flotten
TWI772928B (zh) * 2020-10-21 2022-08-01 行政院原子能委員會核能研究所 非放射性標準品β-CFT之製備方法
CN115572289A (zh) * 2022-10-24 2023-01-06 龙曦宁（上海）医药科技有限公司 一种特索芬辛的合成方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281130A (en) * 1979-05-24 1981-07-28 Sterling Drug Inc. Lower-alkyl 4,6,7,8,8a-9-hexahydro-6,9-ethanothieno[3,2-f]indolizine-10-carboxylate
WO1993009814A1 (fr) * 1991-11-15 1993-05-27 Research Triangle Institute Ligands de liaison de recepteur de cocaine
EP0604355A2 (fr) * 1992-12-23 1994-06-29 Neurosearch A/S Composés hétérocycliques substitués par un groupement alkyle
EP0604352A2 (fr) * 1992-12-23 1994-06-29 Neurosearch A/S Composés hétérocycliques substitués par un groupement aryle
EP0604354A2 (fr) * 1992-12-23 1994-06-29 Neurosearch A/S Composés antidépressifs et anti-parkinsoniens
WO1995028401A1 (fr) * 1994-04-19 1995-10-26 Neurosearch A/S Derives de tropane-2-aldoxime en tant qu'inhibiteurs de recaptage des neurotransmetteurs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380848A (en) * 1990-08-09 1995-01-10 Research Triangle Institute Cocaine receptor binding ligands
US5128118A (en) * 1990-08-09 1992-07-07 Research Triangle Institute Cocaine receptor binding ligands
US5496953A (en) 1990-08-09 1996-03-05 Research Triangle Institute Cocaine receptor binding ligands
GB9626611D0 (en) * 1996-12-20 1997-02-05 Unilever Plc Agglomerated silicas

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281130A (en) * 1979-05-24 1981-07-28 Sterling Drug Inc. Lower-alkyl 4,6,7,8,8a-9-hexahydro-6,9-ethanothieno[3,2-f]indolizine-10-carboxylate
WO1993009814A1 (fr) * 1991-11-15 1993-05-27 Research Triangle Institute Ligands de liaison de recepteur de cocaine
EP0604355A2 (fr) * 1992-12-23 1994-06-29 Neurosearch A/S Composés hétérocycliques substitués par un groupement alkyle
EP0604352A2 (fr) * 1992-12-23 1994-06-29 Neurosearch A/S Composés hétérocycliques substitués par un groupement aryle
EP0604354A2 (fr) * 1992-12-23 1994-06-29 Neurosearch A/S Composés antidépressifs et anti-parkinsoniens
WO1995028401A1 (fr) * 1994-04-19 1995-10-26 Neurosearch A/S Derives de tropane-2-aldoxime en tant qu'inhibiteurs de recaptage des neurotransmetteurs

Cited By (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1118674A4 (fr) * 1998-09-30 2005-05-25 Nihon Mediphysics Co Ltd Procede de production d'un derive d'acide tropinone-monocarboxylique optiquement actif
EP1118674A1 (fr) * 1998-09-30 2001-07-25 Nihon Medi-Physics Co., Ltd. Procede de production d'un derive d'acide tropinone-monocarboxylique optiquement actif
US7994128B2 (en) 1998-10-02 2011-08-09 Xenome Limited Conotoxin peptides useful as inhibitors of neuronal amine transporters
US6794361B1 (en) 1998-10-02 2004-09-21 The University Of Queensland Peptides
US7326682B2 (en) 1998-10-02 2008-02-05 Xenome Limited Conotoxin peptides
WO2002102801A1 (fr) * 2001-05-23 2002-12-27 Neurosearch A/S Derives du tropane et utilisation de ces derniers comme inhibiteurs de recaptage du neurotransmetteur monoamine
WO2003045388A1 (fr) * 2001-11-30 2003-06-05 Neurosearch A/S Derives de tropane possedant une activite inhibitrice de recaptage de dopamine destines au traitement de maladies ischemiques
US7381733B2 (en) 2001-11-30 2008-06-03 Neurosearch A/S Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
AU2003227520B2 (en) * 2002-05-30 2008-05-01 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
US7459464B2 (en) 2002-05-30 2008-12-02 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
WO2003101453A1 (fr) * 2002-05-30 2003-12-11 Neurosearch A/S Triple inhibiteurs de recaptage de momoamine pour le traitement de douleur chronique
AU2003227520B9 (en) * 2002-05-30 2008-06-26 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
WO2004039778A1 (fr) 2002-11-01 2004-05-13 Neurosearch A/S Nouveaux derives de piperidine et leur utilisation en tant qu'inhibiteurs de recaptage de neurotransmetteurs de la monoamine
US7507717B2 (en) 2002-12-02 2009-03-24 Xenome Ltd. Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)
US7851444B2 (en) 2002-12-02 2010-12-14 Xenome Ltd. χ-conotoxin peptides (-1)
WO2004072071A1 (fr) 2003-02-12 2004-08-26 Neurosearch A/S 8 nouveaux derives de 8-aza-bicyclo[3.2.1]octane et leur utilisation en tant qu'inhibiteurs du recaptage des neurotransmetteurs monoamines
US7250425B2 (en) 2003-02-12 2007-07-31 Neurosearch A/S 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7247643B2 (en) 2003-02-12 2007-07-24 Neurosearch A/S 8-aza-bicyclo (3.2.1) octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2004072075A1 (fr) 2003-02-12 2004-08-26 Neurosearch A/S Nouveaux derives de 8-aza-bicyclo[3.2.1]octane et leur utilisation en tant qu'inhibiteurs du recaptage des neurotransmetteurs monoamines
CN100368409C (zh) * 2003-06-24 2008-02-13 神经研究公司 8-氮杂双环[3.2.1]辛烷衍生物及其用于制备单胺神经递质再摄取抑制剂的用途
US7407970B2 (en) 2003-06-24 2008-08-05 Neurosearch A/S 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7888358B2 (en) 2003-06-24 2011-02-15 Neurosearch A/S 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7700619B2 (en) 2003-07-31 2010-04-20 Neurosearch A/S 2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts
WO2005011694A1 (fr) * 2003-07-31 2005-02-10 Neurosearch A/S Sels de 2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1] octane tartrate
US7309790B2 (en) 2003-10-03 2007-12-18 Pfizer Inc Chemical compounds
JP2007508336A (ja) * 2003-10-16 2007-04-05 ニューロサーチ、アクティーゼルスカブ モノアミン神経伝達物質再取り込みインヒビター及びアセチルコリンエステラーゼインヒビターを含む医薬組成物
AU2004283425B2 (en) * 2003-10-16 2010-07-08 Neurosearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
WO2005039580A1 (fr) 2003-10-16 2005-05-06 Boehringer Ingelheim International Gmbh Composition pharmaceutique comprenant un inhibiteur de la recapture des neurotransmetteurs de monoamine et un inhibiteur de l'acetylcholinesterase
EP2269608A2 (fr) 2003-10-16 2011-01-05 NeuroSearch AS Compositions pharmaceutiques comprenants des inhibiteurs de récaptage de neurotransmitteurs monoamine et des inhibiteurs de l'acétylcholinestérase
EP2269608A3 (fr) * 2003-10-16 2011-02-16 NeuroSearch AS Compositions pharmaceutiques comprenants des inhibiteurs de récaptage de neurotransmitteurs monoamine et des inhibiteurs de l'acétylcholinestérase
JP2007511559A (ja) * 2003-11-18 2007-05-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 固形医薬製剤
JP2011068690A (ja) * 2003-11-18 2011-04-07 Boehringer Ingelheim Internatl Gmbh 固形医薬製剤
WO2005049024A2 (fr) * 2003-11-18 2005-06-02 Boehringer Ingelheim International Gmbh Forme de preparation pharmaceutique solide
WO2005049024A3 (fr) * 2003-11-18 2006-03-30 Boehringer Ingelheim Int Forme de preparation pharmaceutique solide
WO2005070428A1 (fr) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Composition pharmaceutique contenant un inhibiteur de la recapture de neurotransmetteurs monoamine et un agoniste de la dopamine
WO2005070427A1 (fr) 2004-01-22 2005-08-04 Neurosearch A/S Composes utilises pour perdre du poids de maniere durable
WO2005070429A1 (fr) * 2004-01-22 2005-08-04 Neurosearch A/S Preparation pharmaceutique contenant un inhibiteur de recapture du neurotransmetteur monoamine et un antagoniste des recepteurs du n-methyl-d-aspartate (nmda)
AU2005205880B2 (en) * 2004-01-22 2010-06-10 Neurosearch A/S Compounds for the sustained reduction of body weight
CN1910180B (zh) * 2004-01-31 2010-05-12 神经研究公司 制备2-(乙氧基甲基)-托烷衍生物的方法
US7544802B2 (en) 2004-01-31 2009-06-09 Neurosearch A/S Process for the preparation of 2-(ethoxymethyl)-tropane derivatives
WO2005073228A1 (fr) 2004-01-31 2005-08-11 Neurosearch A/S Procede pour produire un derive de 2-(ethoxymethyl)-tropane
DE102004004965A1 (de) * 2004-01-31 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung eines 2-(Ethoxymethyl)-tropanderivates
DE102004004965B4 (de) * 2004-01-31 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung eines 2-(Ethoxymethyl)-tropanderivates
WO2005123728A1 (fr) * 2004-06-18 2005-12-29 Neurosearch A/S Nouveaux derives de 9-aza-bicyclo[3.3.1]nonane et leur utilisation comme inhibiteurs du recaptage des neurotransmetteurs monoamines
US7524958B2 (en) 2004-06-18 2009-04-28 Neurosearch A/S Certain 9-aza-bicyclo[3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7915419B2 (en) 2004-06-18 2011-03-29 Neurosearch A/S Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7547788B2 (en) 2004-06-18 2009-06-16 Neurosearch A/S Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2005123679A2 (fr) 2004-06-18 2005-12-29 Neurosearch A/S Nouveaux derives de piperidine substitues par alkyle et leur utilisation comme inhibiteurs de recaptage de neurotransmetteur de monoamine
US8410271B2 (en) 2004-09-30 2013-04-02 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP2284170A1 (fr) 2004-09-30 2011-02-16 NeuroSearch AS Noveaux derivés de chromene-2-one et leur utilisation comme inhibiteurs de recapture du neurotransmetteur monoamine
WO2006084870A2 (fr) 2005-02-10 2006-08-17 Neurosearch A/S Nouveaux derives d'homopiperazine substitues alkyle et leur utilisation en tant qu'inhibiteurs du recaptage des neurotransmetteurs de monoamine
EP2272847A1 (fr) 2005-04-08 2011-01-12 NeuroSearch A/S Enantiomères et leur utilisation comme inhibiteurs du recaptage des neurotransmetteurs monoamine
WO2007000465A1 (fr) * 2005-06-28 2007-01-04 Neurosearch A/S Nouveaux derives de 3-aza-spiro[5.5]undecane et leur utilisation comme inhibiteurs de la recapture des neurotransmetteurs monoaminergiques
US8049012B2 (en) 2005-06-28 2011-11-01 Neurosearch A/S 3-aza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
JP2009500440A (ja) * 2005-07-12 2009-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 性欲障害治療用医薬組成物
WO2007011820A2 (fr) 2005-07-15 2007-01-25 Amr Technology, Inc. Tetrahydrobenzazepines substituees par aryle et heteroaryle, et leur utilisation pour bloquer la reabsorption de la noradrenaline, de la dopamine, et de la serotonine
EP1779851A1 (fr) 2005-10-31 2007-05-02 Boehringer Ingelheim Pharma GmbH & Co.KG Traitement du diabète
US8202884B2 (en) 2005-10-31 2012-06-19 Neurosearch A/S Treatment of type 2 diabetes
US8110586B2 (en) 2005-11-11 2012-02-07 Neurosearch A/S 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2007054531A1 (fr) * 2005-11-11 2007-05-18 Neurosearch A/S Dérivés de 8-aza-bicyclo[3.2.1]octane et leur utilisation en tant qu'inhibiteurs de recapture de neurotransmetteur monoamine
US7700596B2 (en) 2006-02-10 2010-04-20 Neurosearch A/S 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2007093604A1 (fr) 2006-02-17 2007-08-23 Neurosearch A/S Nouveaux dérivés de chromen-2-one et leurs utilisation en tant qu'inhibiteurs de recaptage d'un neuro-transmetteur monoamine
EP2311835A1 (fr) 2006-02-17 2011-04-20 NeuroSearch AS Nouveaux dérivés de chromen-2-one et leurs utilisation en tant qu'inhibiteurs de recaptage d'un neuro-transmetteur monoamine
EP2255848A2 (fr) 2006-09-04 2010-12-01 NeuroSearch AS Combinaisons pharmaceutiques contenant un modulateur du récepteur de la nicotine et un facilitateur cognitif
US8263611B2 (en) 2007-03-01 2012-09-11 Neurosearch A/S Hydrochloride salt of an azabicyclo[3.2.1]octane derivative
WO2008104584A1 (fr) * 2007-03-01 2008-09-04 Glaxo Group Limited Sel chlorhydrate d'un dérivé d'azabicyclo[3.2.1]octane
WO2009034043A1 (fr) * 2007-09-10 2009-03-19 Neurosearch A/S Nouveaux dérivés de phénoxazin-3-one et leur utilisation comme inhibiteurs de la recapture des neurotransmetteurs monoamines
WO2009034042A1 (fr) * 2007-09-10 2009-03-19 Neurosearch A/S Nouveaux dérivés de benzooxazol-2-one et de benzooxathiol-2-one ainsi que leur utilisation comme inhibiteurs de la recapture des neurotransmetteurs monoamines
WO2009065845A1 (fr) * 2007-11-20 2009-05-28 Neurosearch A/S Procédé de traitement des troubles d'hyperphagie
WO2009065846A1 (fr) * 2007-11-20 2009-05-28 Neurosearch A/S Procédé de traitement de l'accoutumance
WO2010132442A1 (fr) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2, 4,]triazolo[1,5,-a]pyridine-6-yl)-4-(3,4-dichlorophényl)-1,2,3,4- tétrahydroisoquinoline et son utilisation
WO2010132487A1 (fr) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company Formes cristallines de (s)-7-([1,2,4]triazolo[1,5-a] pyridin -6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et leurs utilisations
WO2010130620A1 (fr) 2009-05-15 2010-11-18 Neurosearch A/S Dérivés de chromén-2-one et leur utilisation comme inhibiteurs de re-captage de neurotransmetteurs monoamines
WO2011032903A1 (fr) 2009-09-21 2011-03-24 Neurosearch A/S Dérivés de pipérazinyl-alkyl-benzoimidazol-2-one et leur utilisation comme inhibiteurs de recaptage de neurotransmetteurs monoamines
WO2011092061A1 (fr) 2010-01-29 2011-08-04 Neurosearch A/S Dérivés du chromen-2-one et leur utilisation comme inhibiteurs de la recapture des neurotransmetteurs monoamines
WO2011117289A1 (fr) 2010-03-25 2011-09-29 Neurosearch A/S Dérivés de chromén-2-one et leur utilisation à titre d'inhibiteurs de recaptage des neurotransmetteurs monoaminés
WO2012000881A1 (fr) 2010-07-02 2012-01-05 Neurosearch A/S Dérivés de chromén-2-one et leur utilisation comme inhibiteurs de la résorption de neurotransmetteurs monoamine
WO2012024397A2 (fr) 2010-08-17 2012-02-23 Albany Molecular Research, Inc. Dérivés 2,5-méthano- et 2,5-éthano-tétrahydrobenzazépine et utilisation de ceux-ci pour bloquer le recaptage de la norépinéphrine, de la dopamine, et de la sérotonine
US8722662B2 (en) 2010-10-07 2014-05-13 Takeda Pharmaceutical Company Limited Heterocyclic compounds
WO2012046882A1 (fr) 2010-10-07 2012-04-12 Takeda Pharmaceutical Company Limited Dérivés de 1,4-oxazépane
WO2013120935A1 (fr) 2012-02-16 2013-08-22 Neurosearch A/S Compositions pharmaceutiques pour traitement combiné
US9211271B2 (en) 2012-02-16 2015-12-15 Saniona A/S Pharmaceutical compositions for combination therapy
US9387184B2 (en) 2012-02-16 2016-07-12 Saniona A/S Pharmaceutical compositions for combination therapy
WO2016138908A1 (fr) 2015-03-03 2016-09-09 Saniona A/S Formulation à base de combinaison de tésofensine et de bêta-bloquant
US9579288B2 (en) 2015-03-03 2017-02-28 Saniona A/S Tesofensine and beta blocker combination formulations
US11426383B2 (en) 2015-03-03 2022-08-30 Saniona A/S Tesofensine and beta blocker combination formulations
US10231951B2 (en) 2015-03-03 2019-03-19 Saniona A/S Tesofensine, beta blocker combination formulation
US10537551B2 (en) 2015-03-03 2020-01-21 Saniona A/S Tesofensine and beta blocker combination formulations
US12016840B2 (en) 2015-03-03 2024-06-25 Saniona A/S Tesofensine and beta blocker combination formulations
US10828278B2 (en) 2015-03-03 2020-11-10 Saniona A/S Tesofensine and beta blocker combination formulations
WO2017121432A1 (fr) 2016-01-15 2017-07-20 Saniona A/S Tésofensine et métoprolol pour le traitement de l'hypertension
US12178810B2 (en) 2016-01-15 2024-12-31 Saniona A/S Tesofensine and metoprolol for treatment of hypertension
WO2017144978A1 (fr) * 2016-02-25 2017-08-31 Замертон Холдинге Лимитед Sels de (1r,2r,3s)-3-(3,4-dichlorophényl)-2-(étoxyméthyl)-8-méthyl-8-azabicyclo[3.2.1]octane et d'acétalaminoacides optiquement actifs et leur utilisation pour le traitement de troubles liés à l'obésité
WO2018046599A1 (fr) 2016-09-07 2018-03-15 Saniona A/S Compositions de tesofensine
US9949964B2 (en) * 2016-09-07 2018-04-24 Saniona A/S Tesofensine compositions
WO2020144146A1 (fr) 2019-01-07 2020-07-16 Saniona A/S Tesofensine pour la réduction du poids corporel chez des patients prader-willi
WO2021214233A1 (fr) 2020-04-22 2021-10-28 Saniona A/S Traitement de l'obésité hypothalamique
WO2024008808A1 (fr) 2022-07-08 2024-01-11 Initiator Pharma A/S Composé pour le traitement d'un dysfonctionnement sexuel féminin
WO2024089247A1 (fr) 2022-10-28 2024-05-02 Initiator Pharma A/S Composé pour le traitement de la douleur
WO2024146892A1 (fr) 2023-01-03 2024-07-11 Initiator Pharma A/S Composé pour le traitement d'un dysfonctionnement érectile
WO2025051846A1 (fr) 2023-09-05 2025-03-13 Initiator Pharma A/S Composé pour le traitement d'un dysfonctionnement sexuel féminin

Also Published As

Publication number Publication date
US6395748B2 (en) 2002-05-28
US20020128284A1 (en) 2002-09-12
CZ252098A3 (cs) 1998-11-11
BR9707636A (pt) 1999-07-27
NO318731B1 (no) 2005-05-02
JP3238414B2 (ja) 2001-12-17
SK281813B6 (sk) 2001-08-06
ATE203023T1 (de) 2001-07-15
CA2244773A1 (fr) 1997-08-28
PL185132B1 (pl) 2003-02-28
HUP9901199A2 (hu) 1999-08-30
HUP9901199A3 (en) 2001-02-28
DK0885220T3 (da) 2001-10-15
CN1211982A (zh) 1999-03-24
EP0885220B1 (fr) 2001-07-11
ES2159839T3 (es) 2001-10-16
KR100446571B1 (ko) 2004-11-03
EE04751B1 (et) 2006-12-15
HK1018957A1 (en) 2000-01-14
SK92998A3 (en) 1998-11-04
US6288079B1 (en) 2001-09-11
DE69705608T2 (de) 2002-05-16
IL125146A0 (en) 1999-01-26
RU2167876C2 (ru) 2001-05-27
AU720358B2 (en) 2000-06-01
DE69705608D1 (de) 2001-08-16
JP2000504739A (ja) 2000-04-18
US20010018444A1 (en) 2001-08-30
EE9800254A (et) 1999-02-15
CN1077574C (zh) 2002-01-09
NO983877D0 (no) 1998-08-21
CZ287007B6 (en) 2000-08-16
AU1794097A (en) 1997-09-10
KR19990087127A (ko) 1999-12-15
GR3036829T3 (en) 2002-01-31
ZA971525B (en) 1997-10-21
IL125146A (en) 2002-03-10
UA49872C2 (uk) 2002-10-15
EP1130020A1 (fr) 2001-09-05
PL328503A1 (en) 1999-02-01
CA2244773C (fr) 2006-01-03
PT885220E (pt) 2001-11-30
HU228356B1 (en) 2013-03-28
BG63945B1 (bg) 2003-07-31
IS1824B (is) 2002-10-01
SG99853A1 (en) 2003-11-27
NO983877L (no) 1998-08-21
NZ330886A (en) 1999-02-25
BG102637A (en) 1999-06-30
IS4825A (is) 1998-08-17
SI0885220T1 (en) 2001-12-31
EP0885220A1 (fr) 1998-12-23
TR199801641T2 (xx) 1998-11-23

Similar Documents

Publication Publication Date Title
US6288079B1 (en) Tropane-derivatives, their preparation and use
EP0859777B1 (fr) Derives de 8-azabicyclo(3.2.1)oct-2-ene, leur preparation et leur utilisation
US5998405A (en) Fused tropane-derivatives as neurotransmitter reuptake inhibitors
EP0756596B1 (fr) Derives de tropane-2-aldoxime en tant qu&#39;inhibiteurs de recaptage des neurotransmetteurs
US6376673B1 (en) Piperidine derivatives as neurotransmitter re-uptake inhibitors
MXPA98003554A (en) Frozen tropan derivatives, its preparation and

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97192505.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1997903355

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 92998

Country of ref document: SK

Ref document number: 330886

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 09101524

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2244773

Country of ref document: CA

Ref document number: 2244773

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1998-2520

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1019980706518

Country of ref document: KR

Ref document number: 1998/01641

Country of ref document: TR

Ref document number: PA/A/1998/006837

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1199800801

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: PV1998-2520

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1997903355

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980706518

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: PV1998-2520

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1997903355

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019980706518

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载